Update shared on 06 Dec 2025
Narrative Update
Analysts have nudged their price target on Bora Pharmaceuticals slightly higher to approximately $789 per share, reflecting modestly improved long term profit margin expectations, even though projected revenue growth has been tempered slightly.
Valuation Changes
- Fair Value Estimate: unchanged at approximately NT$788.87 per share, indicating no material revision to the intrinsic value assessment.
- Discount Rate: effectively stable at about 5.23 percent, reflecting no meaningful shift in the perceived risk profile.
- Revenue Growth: edged down slightly from roughly 21.29 percent to 21.19 percent, signaling a modestly more conservative top line outlook.
- Net Profit Margin: risen slightly from about 20.47 percent to 20.52 percent, implying a small improvement in long term profitability assumptions.
- Future P/E: essentially unchanged at around 15.03 times, suggesting a steady forward valuation multiple despite the minor underlying estimate tweaks.
Have other thoughts on Bora Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.